Market Place
Sourcing Support
FDA declines to approve Camurus` rare hormone disorder drug
23 Oct 2024 //
REUTERS
Indivior shares soar on $100 mln buyback, opioid addiction drug sales rise
25 Jul 2024 //
REUTERS
Camurus Announces Positive Phase 3 Results For Octreotide SC Depot In Acromegaly
15 Jul 2024 //
PR NEWSWIRE
Camurus announces Phase 3 data reinforcing safety and efficacy of CAM2029
17 Jul 2023 //
PR NEWSWIRE
Camurus announces FDA approval of Brixadi
23 May 2023 //
PR NEWSWIRE
FDA grants ODD status to Camurus’ CAM2029 to treat polycystic liver disease
17 Sep 2021 //
PHARMABIZ
Camurus announces PDUFA date for Brixadi
28 Jun 2021 //
PR NEWSWIRE
Camurus announces Braeburn resubmits New Drug Application for Brixadi in the US
16 Jun 2021 //
PRNEWSWIRE
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
15 Jun 2021 //
PRNEWSWIRE
Camurus announces publication showing superior patient treatment satisfaction
10 May 2021 //
PRNEWSWIRE
Australian TGA approves key label updates to Buvidal®
03 May 2021 //
PRNEWSWIRE
Camurus, Accord, Swedish Orphan Biovitrum (Sobi), Strides Pharma, BI
03 Mar 2021 //
PMCPA
Camurus Announces Submission of Request for Final Approval of Brixadi™
01 Jun 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.